Salvatore Perrone

Latina, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.

Journal: Blood cancer journal
Published: February 20, 2026

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.

Journal: Cancer
Published: February 10, 2026

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Journal: Annals of hematology
Published: January 30, 2026

A case of T-prolymphocytic leukemia harboring RAS mutation.

A case of T-prolymphocytic leukemia harboring RAS mutation.

Journal: Annals of hematology
Published: December 31, 2025

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: December 04, 2025

How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.

How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.

Journal: Journal of clinical medicine
Published: October 31, 2025

CPX-351 in secondary/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients.

CPX-351 in secondary/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients.

Journal: Haematologica
Published: October 21, 2025

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Journal: Annals of hematology
Published: August 30, 2025

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Journal: American journal of hematology
Published: August 08, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: July 29, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances
Published: May 19, 2025

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Journal: Blood advances
Published: May 19, 2025
Showing 1-12 of 69

Last Updated: 09/26/2026